Report Sections

See All Reports

  • COVID-19, SARS-CoV-2 Vaccine
  • COVID-19 (39) SARS-CoV-2 (39) vaccine (18) Vaccine (14) Safety (11) Coronavirus (10) Immunogenicity (9) SARS-CoV-2 Vaccine (7) Virus Diseases (6) Ad5 (5) COVID-19 Vaccine (5) COVID-19 vaccine (5) vector vaccine (5) BCG (4) Coronavirus Disease 2019 (4) Covid19 (4) coronavirus (4) COVID (3) COVID 19 (3) Coronavirus infection (3) Covid-19 (3) Dose-escalation (3) Messenger RNA (3) Moderna (3) Protection against COVID-19 (3) RNA Vaccine (3) Recombinant vaccine (3) SARS (3) adenoviral vector (3) mRNA-1273 (3) mRNA-1273 vaccine (3) Ad5-nCoV (2) Adenovirus Vector (2) BCG vaccine (2) COVID-19 Prevention (2) COVID19 (2) ChAdOx1 nCov19 (2) Convalescent plasma (2) DNA vaccine (2) Electroporation (2) Health care workers (2) Immunogencity (2) Passive immunization (2) Prevention (2) Reactogenicity (2) SARS-CoV 2 (2) SARS-CoV-2 infection (2) Severe acute respiratory syndrome coronavirus 2 (2) Sputnik V (2) Tolerability (2) Transfusion (2) covid-19 (2) immunogenicity (2) infectious respiratory diseases (2) novel coronavirus (2) sars-cov-2 (2) 2019 novel coronavirus (1) 2019-nCoV (1) 2019-nCoV (mRNA-1273) (1) ACE2 (1) ARDS (1) AT1 (1) AZD1222 vaccine (1) AZD1222 vaccine for COVID-19 Prevention (1) Ad26 (1) Ad26COVS1 (1) Adenovirus V (1) AlloStim (1) Alvelestat (1) Antibodies, Neutralizing (1) Antibodies, viral/blood (1) Antibody (1) BACILLUS CALMETTE-GUÉRIN VACCINATION (1) BBV152 (1) BCG Vaccination (1) BCG Vaccine (1) Bacille Calmette-Guérin (1) Bacillus Calmette-Guerin (1) Bacillus Calmette-Guérin vaccination (1) Blinded (1) CEPI (1) COVID 19 Vaccine (1) COVID 19 Vaccine Arcturus (1) COVID 2019 (1) COVID-1 (1) COVID-19 infection (1) COVID-19 serotherapy (1) COVID-19, Convalescent plasma therapy (1) COVID-19, SARS-CoV-2 Vaccine (1) COVID-19, Vaccine (1) COVID-2019 (1) COVID19 ( Corona Virus Disease -2019) (1) Clinical trials (1) Coronavirus Infection (1) Coronavirus Infections / therapy (1) Coronavirus Virus Diseases (1) Covid 19 (1) Covid-19 CTL (1) Covid19 Vaccine (1) Covigenix VAX-001 (1) Critically ill COVID-19 patients (1) EGF (1) Endosomal toll-like receptor 3 (1) EpiVacCorona (1) Fibrosis secondary to Covid19 infection (1) Gamaleya (1) Health Workers (1) Healthcare workers (1) Healthy (1) Herpes Zoster (1) Heterologous effects (1) Heterologous prime-boost vaccination (1) Human (1) IFN type1 (1) IFNγ enzyme-linked immune absorbent spot (ELISpot) (1) IN01 vaccine (1) INO-4800 (1) Immunemo (1) Immunemodulation (1) Immunization, Passive (1) Immunoglobulin (1) Immunoglobulin fragments (1) Immunologic Factors (1) Immunology (1) Inactivated SARS-CoV-2 Vaccine (1) Inactivated vaccine (1) Inactive Vaccine (1) Infectiology (1) Infection (1) Innate immune training (1) Interferon Gamma (1) Intranasal Vaccine (1) Intravenous Immunoglobulin (IVIG) (1) Isotretinoin (1) LV-DC vaccine (1) Lentiviral vector (1) Lentiviral vector, Covid-19/aAPC vaccine (1) M-M-R II ® (1) MMR vaccine (1) MMR vaccine, Respiratory failure, (1) MVA (1) Non-specific effects of BCG (1) Pandemics (1) Passive Immunization (1) Phase I (1) Pooled convalescent Plasma (1) QazCovid-in®, vaccine, III phase, efficiency, safety, immunogenicity (1) RNA COVID 19 (1) Randomized controlled (1) Recombinant Novel Coronavirus Vaccine (1) Respiratory disease (1) Retrospective Studies (1) SARS (Severe Acute Respiratory Syndrome) (1) SARS CoV 2 (1) SARS-COV-2 (1) SARS-CoV Infection (1) SARS-CoV-2 (Severe Acute respiratory syndrome Coronavirus 2) (1) SARS-CoV-2-specific serum neutralising antibody titer (1) SARS-CoV-2-surrogate viral neutralising antibody (1) SARS-Cov2 spike protein-binding IgG antibody titer (1) SARS-Cov2 spike protein-specific CD4+ and CD8+ T-cells responses (1) SARS-Cov2 spike protein-specific Th1/Th2 polarisation (1) Sars-Cov-2 Virus Infection (1) Sepsis (1) Severe Acute Respiratory Syndrome (SARS) (1) Severe COVID-19 patients (1) Sputnik (1) Systems Biology (1) T Cells (1) Therapeutic Vaccine (1) Transmission (1) VLA2001 (1) VXA-C0V2-1 (1) Vaccination (1) Vaccinology (1) Vaxart oral vaccine (1) adaptive design (1) adenoviral vector vaccine (1) adenovirus vector (1) adjuvant (1) adult (1) allergy and immunology (1) anti-infective (1) clinical trial (1) corona virus infection (1) coronavirus disease 2019 (1) dendritic cell (1) dose-finding (1) efficacy (1) exploratory efficacy (1) healthy adults (1) healthy elderlies (1) healthy volunteer (1) inactivated vaccine (1) inactivated-adjuvanted Sars-Cov-2 virus vaccine (1) infection (1) inflammation (1) intravenous immunogloulin therapy (1) live attenuated (1) live attenuated vaccine (1) lung disease (1) myeloid-derived suppressor cells (1) novel lipid nanoparticles (LNPs)-encapsulated mRNA-based vaccine (1) off-target effects (1) pandemic (1) passive immunization (1) pneumonia (1) preemptive (1) prevention (1) prophylaxis (1) rAd26-S (1) reactivity (1) respiratory disease (1) safety (1) self amplifying RNA vaccine (1) tablet vaccine (1) therapeutic vaccine (1) tolerability (1) trained immunity (1) trained innate immunity (1) vaccination (1) vaccine, I/II phase, safety, immunogenicity, QazCovid-in® (1) vector (1)

    COVID-19, SARS-CoV-2 Vaccine

    This report considers only clinical trials that are associated with COVID-19 vaccines.

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (4)


    Name (Synonyms) Correlation
    drug3900 intramuscular accine Wiki 1.00
    drug917 CoronaVac Wiki 1.00
    drug1710 Intramuscular injection Wiki 0.71
    Name (Synonyms) Correlation
    drug2490 Placebo Wiki 0.13

    Correlated MeSH Terms (1)


    Name (Synonyms) Correlation
    D018352 Coronavirus Infections NIH 0.16

    Correlated HPO Terms (0)


    Name (Synonyms) Correlation

    Clinical Trials

    Navigate: Correlations   HPO

    There is one clinical trial.


    1 Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated

    This study is a randomized, double-blinded, and placebo controlled phase III clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research & Development Co., Ltd. The purpose of this study is to evaluate the efficacy, safety and immunogenicity of the experimental vaccine in healthy adults aged 18~59 Years.

    NCT04582344
    Conditions
    1. COVID-19
    Interventions
    1. Biological: CoronaVac
    2. Biological: Placebo

    Primary Outcomes

    Description: The protection rate of a two-dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed symptomatic COVID-19

    Measure: Protection Indexes of Two Vaccine Doses For Symptomatic COVID-19

    Time: 2 weeks after the second dose of vaccination

    Secondary Outcomes

    Description: The protection rate of, at least, one dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed symptomatic COVID-19 Two weeks after the last dose vaccination.

    Measure: Protection Indexes of One Vaccine Dose For Symptomatic COVID-19

    Time: 2 weeks after the second dose of vaccination

    Description: The protection rate of a two-dose of SARS-CoV-2 (Vero Cell) vaccine against rates of hospitalization, disease severity/and death two weeks after the second dose of vaccination

    Measure: Protection Indexes of Second Vaccine Dose For Hospitalization, Disease Severity/and Death

    Time: 2 weeks after the second dose of vaccination

    Description: The protection rate of a two dose of SARS-CoV-2 (Vero Cell) vaccine against RT-PCR confirmed SARS-CoV-2 infection two weeks after the second dose of vaccination

    Measure: Protection Indexes of Two Vaccine Doses For SARS-CoV-2 infection

    Time: 2 weeks after the second dose of vaccination

    Description: The incidence of adverse reactions from the day of first vaccination to 28 days after the second dose of vaccination.

    Measure: Safety indexes of adverse reactions in 28 days

    Time: 28 days after the second dose of vaccination

    Description: The incidence of adverse reactions within 7 days after each dose of vaccination

    Measure: Safety indexes of adverse reactions in 7 days

    Time: 7 days after each dose of vaccination

    Description: The incidence of SAEs from the first vaccination to one year after the second dose vaccination

    Measure: Safety indexes of serious adverse events in 1 year

    Time: 1 year after second dose of vaccination

    Description: The seroconversion rate, seropositivity rate 14 days after each dose vaccination

    Measure: Immunogenicity parameters (seroconversion rate, seropositivity rate) in 14 days

    Time: 14 days after each dose vaccination

    Description: The seroconversion rate, seropositive rate 28 days after the second dose vaccination

    Measure: Immunogenicity parameters (seroconversion rate, seropositivity rate) in 28 days

    Time: 28 days after the second dose vaccination

    Description: GMT and GMI of neutralizing antibody and IgG 14 days after each dose vaccination

    Measure: Immunogenicity parameters (GMT and GMI of neutralizing antibody and IgG) in 14 days

    Time: 14 days after each dose vaccination

    Description: GMT and GMI of neutralizing antibody and IgG 28 days after the second dose vaccination

    Measure: Immunogenicity parameters (GMT and GMI of neutralizing antibody and IgG) in 28 days

    Time: 28 days after the second dose vaccination

    No related HPO nodes (Using clinical trials)


    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    No related HPO nodes (Using clinical trials)


    Reports

    Data processed on January 01, 2021.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook